NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...

Sarepta Therapeutics's revenues have an average growth rate of 29.5% with operating expenses growing at 14.4%. The company's ...

The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...